Nls Pharmaceutics LTD F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
NLS Pharmaceutics has filed an F-1 registration statement for the resale of up to 5 million common shares by Alpha Capital Anstalt, tied to a $25 million equity facility, and detailed its pending merger with Kadimastem Ltd.
NLS Pharmaceutics and Kadimastem have entered into a binding term sheet for a reverse triangular merger, pending due diligence and regulatory approvals.
NLS Pharmaceutics is registering the resale of up to 3.5 million common shares by selling shareholders, which are issuable upon the exercise of warrants from a prior private placement.